{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:13:52Z","timestamp":1790925232597,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007914","name":"The University of Texas Southwestern Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Addictive Behaviors Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.abrep.2026.100671","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:14:58Z","timestamp":1769793298000},"page":"100671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov"],"prefix":"10.1016","volume":"23","author":[{"given":"Shruti","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish K.","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abrep.2026.100671_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: A narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.abrep.2026.100671_b0010","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (APA) (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https:\/\/doi.org\/10.1176\/appi.books.9780890425596.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"1","key":"10.1016\/j.abrep.2026.100671_b0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.abrep.2026.100671_b0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.abrep.2026.100671_b0030","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fphys.2018.00900","article-title":"The gut-brain axis, the human gut microbiota and their integration in the development of obesity","volume":"9","author":"Bliss","year":"2018","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.abrep.2026.100671_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review -Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacological Research"},{"issue":"11","key":"10.1016\/j.abrep.2026.100671_b0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11920-019-1084-2","article-title":"Recent advances in the neurobiology of altered motivation following bariatric surgery","volume":"21","author":"Brutman","year":"2019","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.abrep.2026.100671_b0020","doi-asserted-by":"crossref","unstructured":"Clinical Guideline Committee (CGC) Members, ASAM Team, AAAP Team, & IRETA Team (2024). The ASAM\/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. Journal of addiction medicine, 18 (1S Suppl 1), 1\u201356. https:\/\/doi.org\/10.1097\/ADM.0000000000001299.","DOI":"10.1097\/ADM.0000000000001299"},{"key":"10.1016\/j.abrep.2026.100671_b0045","series-title":"StatPearls: StatPearls Publishing. Copyright \u00a9 2025","article-title":"Glucagon-like peptide-1 receptor agonists","author":"Collins","year":"2025"},{"issue":"7","key":"10.1016\/j.abrep.2026.100671_b0055","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide-semaglutide in adults with overweight or obesity and type 2 Diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.abrep.2026.100671_b0060","article-title":"Incretin dominance and emerging mechanisms in obesity pharmacotherapy: Insights from 275 registered clinical trials (2019-2024)","author":"Dos Santos Barbosa","year":"2025","journal-title":"Therapeutic Innovation & Regulatory Science"},{"key":"10.1016\/j.abrep.2026.100671_b0065","doi-asserted-by":"crossref","unstructured":"Edvardsson, C. E., Adermark, L., Gottlieb, S., Alfreji, S., Emous, T. A., Gouda, Y., Thorsell, A., Vuji\u010di\u0107, M., Aran\u00e4s, C., & Benrick, A. (2025). Tirzepatide attenuates dopamine reward signaling and suppresses alcohol drinking and relapse-like behaviors in rodents. bioRxiv, 2025.2008. 2026.672374.","DOI":"10.1101\/2025.08.26.672374"},{"key":"10.1016\/j.abrep.2026.100671_b0070","series-title":"Opioid use disorder: Endpoints for demonstrating effectiveness of drugs for treatment guidance for industry","author":"Fda","year":"2020"},{"key":"10.1016\/j.abrep.2026.100671_b0075","series-title":"Stimulant use disorders: Developing drugs for treatment. US Department of Health and Human Services Food and Drug Administration","author":"Fda","year":"2023"},{"issue":"10160","key":"10.1016\/j.abrep.2026.100671_b0085","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.abrep.2026.100671_b0080","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.abrep.2026.100671_b0090","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.abrep.2026.100671_b0095","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.abrep.2026.100671_b0100","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1016\/j.abrep.2026.100671_b0105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): A double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"6","key":"10.1016\/j.abrep.2026.100671_b0110","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.abrep.2026.100671_b0115","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly maridebart cafraglutide for the treatment of obesity - a phase 2 trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.abrep.2026.100671_b0120","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.eatbeh.2014.04.019","article-title":"Non-medical use of prescription stimulants for weight loss, disordered eating, and body image","volume":"15","author":"Jeffers","year":"2014","journal-title":"Eating Behaviors"},{"issue":"22","key":"10.1016\/j.abrep.2026.100671_b0125","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-weekly mazdutide in chinese adults with obesity or overweight","volume":"392","author":"Ji","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"19","key":"10.1016\/j.abrep.2026.100671_b0130","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.abrep.2026.100671_b0135","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1038\/s41380-025-03259-8","article-title":"Crosstalk between alcohol use disorder and obesity: Two sides of the same coin?","volume":"30","author":"Leggio","year":"2025","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.abrep.2026.100671_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smokingcessation: A single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.abrep.2026.100671_b0145","doi-asserted-by":"crossref","first-page":"e3152","DOI":"10.1097\/MD.0000000000003152","article-title":"The body mass index, blood pressure, and fasting blood glucose in patients with methamphetamine dependence","volume":"95","author":"Lv","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.abrep.2026.100671_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 Analogues in the neurobiology of addiction: translational insights and therapeutic perspectives","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"issue":"9","key":"10.1016\/j.abrep.2026.100671_b0155","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1038\/s41591-025-03774-9","article-title":"Tirzepatide on ingestive behavior in adults with overweight or obesity: A randomized 6-week phase 1 trial","volume":"31","author":"Martin","year":"2025","journal-title":"Nature Medicine"},{"key":"10.1016\/j.abrep.2026.100671_b0160","doi-asserted-by":"crossref","DOI":"10.1177\/1533317520953041","article-title":"The dual GLP-1\/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP\/PS1 mouse model of alzheimer's disease","volume":"35","author":"Maskery","year":"2020","journal-title":"American Journal of Alzheimer's Disease and Other Dementias"},{"issue":"17","key":"10.1016\/j.abrep.2026.100671_b0165","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder: A systematic review and meta-analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.abrep.2026.100671_b0170","volume":"1","author":"Nielsen","year":"2019","journal-title":"Pharmacotherapies for Cannabis Dependence. The Cochrane Database of Systematic Reviews"},{"issue":"10520","key":"10.1016\/j.abrep.2026.100671_b0175","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/S0140-6736(25)02114-2","article-title":"Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.abrep.2026.100671_b0180","doi-asserted-by":"crossref","first-page":"720","DOI":"10.7326\/M21-4011","article-title":"The management of substance use disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline","volume":"175","author":"Perry","year":"2022","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1016\/j.abrep.2026.100671_b0185","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.abrep.2026.100671_b0190","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Internal Medicine"},{"issue":"11","key":"10.1016\/j.abrep.2026.100671_b0195","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes","volume":"393","author":"Rosenstock","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.abrep.2026.100671_b0200","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMcp2032393","article-title":"Tobacco Addiction","volume":"387","author":"Selby","year":"2022","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.abrep.2026.100671_b0205","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/ADM.0000000000001347","article-title":"The efficacy of GLP-1 agonists in treating substance use disorder in patients: A scoping review","volume":"18","author":"Shen","year":"2024","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.abrep.2026.100671_b0210","doi-asserted-by":"crossref","DOI":"10.1186\/s13722-025-00637-z","article-title":"The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: A systematic review and meta-analysis","author":"Sinha","year":"2025","journal-title":"Addiction Science & Clinical Practice"},{"issue":"778","key":"10.1016\/j.abrep.2026.100671_b0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp5765","article-title":"The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron","volume":"16","author":"Sloop","year":"2024","journal-title":"Science Translational Medicine"},{"issue":"2","key":"10.1016\/j.abrep.2026.100671_b0225","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/add.16626","article-title":"GLP-1R agonist medications for addiction treatment","volume":"120","author":"Volkow","year":"2025","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.abrep.2026.100671_b0220","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1467-789X.2012.01031.x","article-title":"Obesity and addiction: Neurobiological overlaps","volume":"14","author":"Volkow","year":"2013","journal-title":"Obesity Reviews : An Official Journal of the International Association for the Study of Obesit"},{"issue":"8","key":"10.1016\/j.abrep.2026.100671_b0230","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: A retrospective cohort study","volume":"29","author":"Wang","year":"2024","journal-title":"Molecular Psychiatry"},{"issue":"10","key":"10.1016\/j.abrep.2026.100671_b0240","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily Oral GLP-1 Receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"18","key":"10.1016\/j.abrep.2026.100671_b0235","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.abrep.2026.100671_b0245","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2025.2508","article-title":"Reductions in world health organization risk drinking levels as a primary efficacy end point for alcohol clinical trials: A review","author":"Witkiewitz","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.abrep.2026.100671_b0250","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nature Medicine"},{"issue":"10","key":"10.1016\/j.abrep.2026.100671_b0260","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: A pilot randomized controlled trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco"},{"issue":"4","key":"10.1016\/j.abrep.2026.100671_b0255","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ADM.0000000000001147","article-title":"Feasibility of exenatide, a GLP-1R agonist, for treating cocaine use disorder: A case series study","volume":"17","author":"Yammine","year":"2023","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.abrep.2026.100671_b0265","doi-asserted-by":"crossref","DOI":"10.1007\/s40429-025-00657-4","article-title":"The potential utility of glp-1 receptor agonist medications for addiction treatment: A narrative review of clinical and epidemiological evidence","volume":"12","author":"Yammine","year":"2025","journal-title":"Current Addiction Reports"},{"key":"10.1016\/j.abrep.2026.100671_b0270","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2017.06.029","article-title":"A novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease","volume":"812","author":"Yuan","year":"2017","journal-title":"European Journal of Pharmacology"}],"container-title":["Addictive Behaviors Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352853226000076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352853226000076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:11:45Z","timestamp":1783077105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352853226000076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":53,"alternative-id":["S2352853226000076"],"URL":"https:\/\/doi.org\/10.1016\/j.abrep.2026.100671","relation":{},"ISSN":["2352-8532"],"issn-type":[{"value":"2352-8532","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov","name":"articletitle","label":"Article Title"},{"value":"Addictive Behaviors Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abrep.2026.100671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100671"}}